Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and ChallengesMehrdad Hefazi(Mayo Clinic), Bruce R. Blazar(University of Minnesota Medical Center)International Journal of Molecular SciencesSeptember 7, 202110.3390/ijms22189676Cited by 39SaveCiteExport RISWatch citationsRelated PapersCombined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions|Blood|2002|95The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease|Journal of Clinical Investigation|2018|59